Preventive Treatments for Migraine Are Underused
A majority of patients who are eligible for preventive migraine treatment are not taking medication, according to the results of a recent study. Less than 10% of eligible patients currently use a migraine-preventive agent, and an additional 10% had discontinued use.
These findings, presented at the American Academy of Neurology’s 2021 Virtual Annual Meeting, come as a result of the CaMEO study. This web-based survey identified those who met the modified International Classification of Headache Disorders, third edition, criteria for migraine.
Of the 16,789 total patients with migraine included in the survey from September 2012 to November 2013, 39% (n =6579) reported 4 or more monthly headache days and were included in this representative US sample.
The results indicated that a majority of respondents (80.2%) had never used a daily oral migraine-preventive agent. However, 61.8% of these individuals were interested in trying an oral prescription preventive agent, and 40.9% were interested in trying an injectable preventive medication.
Further, 9.8% of respondents reported current use of a daily oral migraine-preventive agent. Of these users, 85.7% were somewhat or very interested in trying an oral, daily preventive medication. Interest in trying an injectable preventive medication was reported by 63.6% of current users.
Previous but not current use was reported in 10.1% of participants. Reasons cited for discontinuing use among prior users were safety and tolerability, as well as insufficient efficacy.
“Treatment gaps in current and discontinued users suggest additional treatment options are needed to improve efficacy and tolerability profiles,” the researchers concluded.
Nahas SJ, Buse DC, Hutchinson S, et al. Characterizing preventive treatment gaps in migraine: results from the CaMEO study. Paper presented at: American Academy of Neurology’s 2021 Virtual Annual Meeting; April 17-22, 2021; Virtual. https://index.mirasmart.com/AAN2021/PDFfiles/AAN2021-001514.html